Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Padcev Broadens Label for Keytruda Combo in China: Astellas
Astellas Pharma said on January 8 that it has won Chinese regulatory approval for the label expansion of its antibody-drug conjugate Padcev (enfortumab vedotin) for a combination therapy with Merck’s PD-1 inhibitor Keytruda (pembrolizumab). The Chinese National Medical Products Administration’s…
To read the full story
Related Article
- Padcev/Keytruda Accepted for China Review in Perioperative MIBC
July 8, 2026
- Padcev Approved for Bladder Cancer in China: Astellas
August 21, 2024
- Padcev Application Accepted for Review in China: Astellas
March 13, 2023
BUSINESS
- FRONTEO, Daiichi Sankyo Build AI Model to Analyze Toxicity Reports
July 15, 2026
- Cell Resources Launches Umbilical Cord- and Amnion-Derived MSCs
July 15, 2026
- iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
- FDA Greenlights Leqembi Iqlik for Alzheimer’s Initiation Therapy
July 14, 2026
- Santen, Kyorin Strike Co-Promotion Deal for Alesion Eyelid Cream
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…